Ehlers, L. H., Lamotte, M., Monteiro, S., Sandgaard, S., Holmgaard, P., Frary, E. C., & Ejskjaer, N. (2021). The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease. Diabetes Therapy, 12(5), 1523. https://doi.org/10.1007/s13300-021-01040-y
Chicago Style (17th ed.) CitationEhlers, Lars Holger, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, and Niels Ejskjaer. "The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease." Diabetes Therapy 12, no. 5 (2021): 1523. https://doi.org/10.1007/s13300-021-01040-y.
MLA (9th ed.) CitationEhlers, Lars Holger, et al. "The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease." Diabetes Therapy, vol. 12, no. 5, 2021, p. 1523, https://doi.org/10.1007/s13300-021-01040-y.
